Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3655 in pre-cirrhotic nonalcoholic steatohepatitis
2019-003048-63Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing MK-3655 dose arm(s) with Placebo (2 arms). Primary endpoint: Percentage of participants with NASH resolution without worsening fibrosis. Started Sep 2020; status: completed.
02
Drugs
NGM313
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-003048-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003048-63.